Cathal Friel on resilience, ambition and Ireland’s future

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these interviews features Cathal Friel, a well-known entrepreneur, who discusses topics such as resilience, ambition, and the ongoing housing crisis with Sarah Freeman.

The conversation took place just weeks before the public announcement of Friel’s €7.3 million sale of shares in hVivo. At 60 years old, Friel’s extensive entrepreneurial portfolio includes co-founding companies such as hVIVO, Poolbeg Pharma, Amryt Pharma, and European Green Transition. He also founded and managed Raglan Capital for 17 years, solidifying his reputation in the business world.

During the interview, Friel, speaking from his rented holiday home in Donegal, fondly recalls childhood memories and emphasises the importance of experiencing life’s challenges to develop a strong work ethic. Growing up as one of 10 children in Donegal, Friel had to leave school at 16 to manage the family business after his father became ill. Despite the hardships, he later put himself through college and earned an MBA in International Marketing.

Friel believes that hunger and ambition often stem from adversity, contrasting his own experience with that of his children, who are growing up comfortably in South County Dublin. He attributes much of his drive to the challenges he faced early in life and asserts that such resilience is built through tough times.

The entrepreneur also reflects on Ireland’s economic resilience following the 2007/2008 financial crisis, which he believes taught the nation valuable lessons in financial prudence. Friel argues that Ireland’s entrepreneurial spirit, particularly among the farming community, has contributed to its current success. He describes farmers as the “oldest entrepreneurs,” given their need to navigate unpredictable factors like weather and market prices.

When addressing the housing crisis, Friel expresses deep concern, noting that high property prices are a significant issue across Europe, particularly in Ireland. He proposes several solutions, including doubling the housing height limits, curbing serial planning objections, and banning judicial reviews of planning applications. Friel also suggests the development of satellite towns, inspired by similar approaches in the Netherlands, to alleviate housing shortages.

Although Friel has strong opinions on policy matters, he dismisses any desire to enter politics, recognising that the skills required differ from those in business. He continues to focus on business opportunities, regularly travelling to London to monitor market trends and investor interests. For Friel, success often lies in recognising where money is flowing, rather than relying on a singular brilliant idea.

Friel’s reflections highlight his enduring passion for business and his belief in the importance of resilience and adaptability in navigating both personal and professional challenges.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Poolbeg receives US patent for Immunomodulator development

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Poolbeg Pharma patent portfolio significantly strengthened & expanded

Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.

UCD leads in research collaboration and Poolbeg Pharma partnership

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

AI’s impact on infectious disease drug development

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma’s innovative POLB001 demonstrates promising potential

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg

John McEvoy: The journey of an Irish unicorn

A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where